Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits.
The effect of atorvastatin (3 mg kg(-1) day(-1)), simvastatin (3 mg kg(-1) day(-1)) and bezafibrate (100 mg kg(-1) day(-1)) administered for 4 weeks to male New Zealand white rabbits on enzyme activities related to lipid metabolism has been studied. Only the statins reduced plasma cholesterol values, while none of the drugs modified plasma triglyceride or high density lipoprotein (HDL)-cholesterol concentrations, nor the activity of enzymes such as hepatic diacylglycerol acyltransferase, lipoprotein lipase or hepatic lipase, directly involved in triglyceride metabolism. Both statins elicited similar increases in the hepatic microsomal 3-hydroxy-3-methyl-glutaryl Coenzyme A (CoA) reductase activity (147 and 109% induction for simvastatin and atorvastatin, respectively), and none of the drugs assayed modified hepatic acyl-coenzyme A:cholesterol acyltransferase activity significantly. Only bezafibrate induced a significant 57% reduction in the activity of hepatic microsomal cholesterol 7alpha-hydroxylase. Regarding the rate limiting enzyme of phosphatidylcholine biosynthesis, CTP:phosphocholine cytidylyl transferase, atorvastatin and bezafibrate behaved similarly, decreasing the enzyme activity in the liver by 45% and 54%, respectively; simvastatin induced no modification of this activity. The reduction of CTP:phosphocholine cytidylyl transferase activity is not caused by a direct inhibition of the enzyme by bezafibrate and atorvastatin. Further, the inhibitory effect of atorvastatin appears to be unrelated to the inhibition of 3-hydroxy-3-methyl-glutaryl CoA reductase elicited in vivo.
Alegret
M
M
Dept. Farmacología y Química Terapéutica, Facultad de Farmacia, Núcleo Universitario de Pedralbes, Barcelona, Spain.
Verd
J C
JC
Díaz
C
C
Hernández
G
G
Adzet
T
T
Sánchez
R M
RM
Laguna
J C
JC
D000217:Acyltransferases / Q000378:metabolism; D000818:Animals; D000069059:Atorvastatin; D001629:Bezafibrate / Q000494:pharmacology; D002784:Cholesterol / Q000378:metabolism; D051048:Diacylglycerol O-Acyltransferase; D006538:Heptanoic Acids / Q000494:pharmacology; D006903:Hydroxymethylglutaryl CoA Reductases / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008055:Lipids / Q000097:blood*; D008099:Liver / Q000187:drug effects* / Q000201:enzymology*; D008297:Male; D010743:Phospholipids / Q000096:biosynthesis; D011758:Pyrroles / Q000494:pharmacology; D011817:Rabbits; D019821:Simvastatin / Q000494:pharmacology; D014280:Triglycerides / Q000378:metabolism
D006538:Heptanoic Acids; D000960:Hypolipidemic Agents; D008055:Lipids; D010743:Phospholipids; D011758:Pyrroles; D014280:Triglycerides; D002784:Cholesterol; D000069059:Atorvastatin; D019821:Simvastatin; D006903:Hydroxymethylglutaryl CoA Reductases; D000217:Acyltransferases; D051048:Diacylglycerol O-Acyltransferase; D001629:Bezafibrate